| Literature DB >> 26266085 |
Alessandra Brocca1, Grazia Maria Virzì2, Chiara Pasqualin2, Silvia Pastori3, Stefano Marcante4, Massimo de Cal2, Claudio Ronco2.
Abstract
Background. Cardiorenal Syndrome Type 5 (CRS Type 5) reflects concomitant cardiac and renal dysfunctions in the setting of a wide spectrum of systemic disorders. Our aim was to study in vitro effects of CRS Type 5 plasma on renal tubular cells (RTCs), in terms of cellular death and the characterization of inflammatory plasma profile in these patients. Material and Methods. We enrolled 11 CRS Type 5 patients from ICU and 16 healthy controls. Plasma from patients and controls was incubated with renal tubular cells (RTCs) and cell death was evaluated. Plasma cytokines were detected. Results. RTCs incubated with CRS Type 5 plasma showed significantly higher apoptosis and necrosis with respect to controls. Plasma cytokine profile of CRS Type 5 patients was significantly different from controls: we observed the production of pro- and anti-inflammatory mediators in these patients. Caspase-3, caspase-8, and caspase-9 were activated in cells treated with CRS Type 5 plasma compared to controls. Conclusions. Our results underline the cytotoxic effect of CRS Type 5 mediators on RTC viability, probably due to the activation of both intrinsic and extrinsic pathways of apoptosis and to the deregulation of cytokine release. The consequence may be the damage of distant organs which lead to the worsening of condition of patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26266085 PMCID: PMC4525149 DOI: 10.1155/2015/469461
Source DB: PubMed Journal: Anal Cell Pathol (Amst) ISSN: 2210-7177 Impact factor: 2.916
Clinical and biochemistry parameter about CRS Type 5 patients enrolled.
| CRS Type 5 patients | |
|---|---|
| Female ( | 3/11 |
| Age (years) | 69.4 ± 10.8 |
| Creatinine baseline (mg/dL) | 1.06 (0.95–1.41) |
| eGFR baseline (mL/min/1.73 m2) | 62 (50–75) |
| Creatinine admission (mg/dL) | 1.85 (0.77–3.64) |
| eGFR admission (mL/min/1.73 m2) | 36 (17.5–86) |
| Temperature (°C) | 38.3 (36.1–38.9) |
| Urine output (mL/day) | 3040 (1542–3225) |
| Urea (mg/dl) | 91 (59–192) |
| Na (mEq/L) | 138 (135–144) |
| K (mEq/L) | 3.9 (3.67–4.1) |
| White blood cells (/mm3) | 10.8 (7.25–14.2) |
| Platelets (/mm3) | 133 (109–149) |
| PaO2/FiO2 | 241.5 (194.5–273.5) |
| Nonsurvivors ( | 3/11 |
| CRRT ( | 4/11 |
Figure 1Evaluation of percentage of viability, necrosis, and apoptosis in RTCs after incubation with plasma from CRS Type 5 patients and healthy controls.
Evaluation of caspase-3, caspase-8, and caspase-9 in RTCs after incubation with CRS Type 5 plasma and controls.
| CRS Type 5 | Controls |
| |
|---|---|---|---|
| Caspase-3 (ng/mL) | 4.54, IQR (4.51–4.60) | 1.04, IQR (0.92–1.57) | <0.01 |
| Caspase-8 (ng/mL) | 0.96, IQR (0.91–1.04) | 0.68, IQR (0.52–0.74) | <0.01 |
| Caspase-9 (ng/mL) | 14.49, IQR (6.71–54.5) | 4.17, IQR (2.28–5.48) | <0.01 |
Evaluation of immune-mediated molecules in CRS Type 5 plasma and controls.
| Parameters | CRS Type 5 | Controls |
|
|---|---|---|---|
| IL-6 (pg/mL) | 64.6 (59.3–83.8) | 5.9 (3.5–7.3) | <0.05 |
| IL-10 (pg/mL) | 19.6 (8.1–54.6) | 3.1 (2.0–3.9) | <0.05 |
| IL-8 (ng/mL) | 87.1 (78.0–119.5) | 20.3 (12.6–47.6) | <0.05 |
| IL-1 | 80.8 (45.9–273.9) | 8.3 (4.3–41.1) | <0.05 |
| IFN- | 17.9 (16.9–20.8) | 2.0 (1.4–3.2) | <0.05 |
Differences in immune-mediated molecules and in vitro viability rates in patients who have undergone CRRT or who did not.
|
| no CRRT | CRRT |
|
|---|---|---|---|
|
|
| ||
| IL-6 (pg/mL) | 59.6 (57.3–79.4) | 128.8 (98.1–155.3) | 0.059 |
| IL-10 (pg/mL) | 19.6 (9.8–54.6) | 16.3 (7.9–86.6) | 0.850 |
| IL-8 (ng/mL) | 78.1 (77.5–86.4) | 119.5 (95.1–341.5) | 0.038 |
| IL-1 | 80.8 (45.1–233.3) | 111.3 (49.8–525.6) | 0.450 |
| IFN- | 19.7 (17.5–30.1) | 17.4 (16.9–17.8) | 0.257 |
| Viability (%) | 82.8 (81.5–85.6) | 83.1 (78.4–85.4) | 0.775 |
| Apoptosis (%) | 15.1 (13.9–17.1) | 15.8 (13.7–17.9) | 0.850 |
| Necrosis (%) | 4.1 (2.2–11.5) | 6.2 (3.2–12.3) | 0.850 |